BBIO vs. AXSM
BBIO (BridgeBio Pharma, Inc.) and AXSM (Axsome Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BBIO returned 8.42%/yr vs 35.01%/yr for AXSM. Their 0.35 correlation means their historical movements had little consistent relationship.
Performance
BBIO vs. AXSM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a 4.71% return, which is significantly lower than AXSM's 19.36% return.
BBIO
- 1D
- -2.50%
- 1M
- 7.47%
- 6M
- 3.65%
- YTD
- 4.71%
- 1Y
- 69.43%
- 3Y*
- 32.71%
- 5Y*
- 8.42%
- 10Y*
- —
- ALL TIME*
- 14.52%
AXSM
- 1D
- -7.10%
- 1M
- -9.42%
- 6M
- 18.31%
- YTD
- 19.36%
- 1Y
- 115.02%
- 3Y*
- 41.26%
- 5Y*
- 35.01%
- 10Y*
- 39.83%
- ALL TIME*
- 34.71%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $153.10M | $171.36M | $209.26M | |
| $163.36M | $283.28M | $252.33M |
BBIO vs. AXSM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | 4.71% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 14.51% |
AXSM Axsome Therapeutics, Inc. | 19.36% | 115.86% | 6.31% | 3.19% | 104.16% | -53.63% | -21.18% | 360.81% |
Correlation
The correlation between BBIO and AXSM is 0.37, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.37 |
Correlation (3Y) Balances recent behavior with more history. | 0.38 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.38 |
Correlation (All Time) Calculated using the full available price history since Jun 27, 2019 | 0.35 |
Fundamentals
BBIO:
$15.69B
AXSM:
$11.22B
BBIO:
-$3.74
AXSM:
-$3.72
BBIO:
27.48
AXSM:
15.58
BBIO:
$566.04M
AXSM:
$708.24M
BBIO:
$538.20M
AXSM:
$655.82M
BBIO:
-$602.24M
AXSM:
-$172.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. AXSM — Risk / Return Rank
BBIO
AXSM
BBIO vs. AXSM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BBIO | AXSM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.25 | ||
| Sortino ratioReturn per unit of downside risk | -1.78 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.47 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 3.45 | 6.25 | -2.81 |
| Martin ratioReturn relative to average drawdown | 7.74 | 18.02 | -10.27 |
Loading charts...
Drawdowns
BBIO vs. AXSM - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for BBIO and AXSM.
Loading charts...
Drawdown Indicators
| BBIO | AXSM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -86.65% | -6.15% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -18.50% | -1.75% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -32.69% | -16.39% |
Max Drawdown (5Y)Largest decline over 5 years | -90.72% | -61.08% | -29.64% |
Max Drawdown (10Y)Largest decline over 10 years | — | -81.26% | — |
Current DrawdownCurrent decline from peak | -11.18% | -14.57% | +3.39% |
Average DrawdownAverage peak-to-trough decline | -45.08% | -39.06% | -6.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.00% | 6.41% | +2.59% |
Volatility
BBIO vs. AXSM - Volatility Comparison
BridgeBio Pharma, Inc. (BBIO) has a higher volatility of 17.23% compared to Axsome Therapeutics, Inc. (AXSM) at 14.94%. This indicates that BBIO's price experiences larger fluctuations and is considered to be riskier than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | AXSM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.23% | 14.94% | +2.29% |
Volatility (6M)Calculated over the trailing 6-month period | 37.06% | 28.72% | +8.34% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.65% | 42.96% | +5.69% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 86.05% | 70.11% | +15.94% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.29% | 90.38% | -7.09% |
Dividends
BBIO vs. AXSM - Dividend Comparison
Neither BBIO nor AXSM has paid dividends to shareholders.
Financials
BBIO vs. AXSM - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BBIO vs. AXSM - Profitability Comparison
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
AXSM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Axsome Therapeutics, Inc. reported a gross profit of 176.48M and revenue of 191.20M. Therefore, the gross margin over that period was 92.3%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
AXSM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Axsome Therapeutics, Inc. reported an operating income of -63.36M and revenue of 191.20M, resulting in an operating margin of -33.1%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
AXSM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Axsome Therapeutics, Inc. reported a net income of -64.54M and revenue of 191.20M, resulting in a net margin of -33.8%.
Frequently Asked Questions
BBIO and AXSM have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BBIO has higher volatility (17.23%) compared to AXSM (14.94%). In terms of maximum drawdown, BBIO dropped -92.80% vs AXSM's -86.65%.
AXSM currently has the higher Sharpe Ratio (2.69 vs 1.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and AXSM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer